7HD Stock Overview
Engages in the wholesale distribution of pharmaceuticals in Poland. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
No risks detected for 7HD from our risk checks.
My Notes
Capture your thoughts, links and company narrative
NEUCA S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł197.60 |
| 52 Week High | zł222.00 |
| 52 Week Low | zł169.40 |
| Beta | 0.45 |
| 1 Month Change | 6.81% |
| 3 Month Change | 4.77% |
| 1 Year Change | 2.17% |
| 3 Year Change | 7.74% |
| 5 Year Change | n/a |
| Change since IPO | 32.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 7HD | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | -2.7% | -0.4% | -0.4% |
| 1Y | 2.2% | 16.1% | 7.9% |
Return vs Industry: 7HD underperformed the German Healthcare industry which returned 16.1% over the past year.
Return vs Market: 7HD underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 7HD volatility | |
|---|---|
| 7HD Average Weekly Movement | 4.3% |
| Healthcare Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 7HD has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 7HD's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 4,633 | Piotr Sucharski | www.neuca.pl |
NEUCA S.A. engages in the wholesale distribution of pharmaceuticals in Poland. It operates through Wholesale Distribution of Medicines, Manufacture of Pharmaceuticals, Medical Operator, Clinical Trials, and Insurance Activities segments. The company owns and produces Rx, OTC medicines, dietary supplements, medical devices, dermocosmetics, hygiene products, personal protective equipment, as well as diagnostic and dressing materials under the Swiat Zdrowia, APTEO, GENOPTIM, CERA+ Solutions, and Kic Kic brand names to pharmacists, medical doctors, and patients.
NEUCA S.A. Fundamentals Summary
| 7HD fundamental statistics | |
|---|---|
| Market cap | €915.81m |
| Earnings (TTM) | €37.81m |
| Revenue (TTM) | €2.89b |
24.2x
P/E Ratio0.3x
P/S RatioIs 7HD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7HD income statement (TTM) | |
|---|---|
| Revenue | zł12.34b |
| Cost of Revenue | zł10.92b |
| Gross Profit | zł1.43b |
| Other Expenses | zł1.26b |
| Earnings | zł161.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 36.13 |
| Gross Margin | 11.55% |
| Net Profit Margin | 1.31% |
| Debt/Equity Ratio | 49.9% |
How did 7HD perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield40%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 00:59 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NEUCA S.A. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Sylwia Jaskiewicz | Dom Maklerski IDMSA |
| Cezary Bernatek | Erste Group Bank AG |
| Lukasz Kosiarski | Ipopema Securities S.A. |